Literature DB >> 807036

Undegraded human immunoglobulin for intravenous use.

W Stephan.   

Abstract

A report is presented on the development and the properties of a nondegraded human immunoglobulin preparation suitable for intravenous administration. Intravenous tolerance is achieved by elimination of anticomplementary activity through modification with beta-propiolactone. The natural antibody characteristics, such as antibody activity, molecular weight, and half-life, are retained. The findings presented open up new perspectives for an extension of the range of indication for intravenous immunoglobulin.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 807036     DOI： 10.1111/j.1423-0410.1975.tb02791.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN： 0042-9007            Impact factor:   2.144


  13 in total

Review 1.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

2.  Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.

Authors:  R I Schiff; L W Williams; R P Nelson; R H Buckley; W Burks; R A Good
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

3.  Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency.

Authors:  R I Schiff; C Rudd
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

4.  Some side effects of intravenous 7S-immunoglobulins are due to immune complexes and can be prevented by 5S-immunoglobulin given prior to 7S treatment.

Authors:  G P Tilz
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

5.  Inactivation of HIV in plasma derivatives by beta-propiolactone and UV irradiation.

Authors:  H Dichtelmüller; W Stephan; A M Prince; L Gürtler; F Deinhardt
Journal:  Infection       Date:  1987       Impact factor: 3.553

6.  Reduced efficacy of sulfitolysed intravenous immunoglobulin.

Authors:  W Stephan; H Dichtelmüller
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

7.  [Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].

Authors:  M S Collins; R F Hector; R E Roby; A A Edwards; D K Ladehoff; J H Dorsey
Journal:  Infection       Date:  1987       Impact factor: 3.553

8.  [Problems of intravenous gammaglobulin therapy (author's transl)].

Authors:  J Ring; K H Duswald
Journal:  Klin Wochenschr       Date:  1980-08-15

9.  Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits.

Authors:  M Iwata; T Shimozato; H Tokiwa; E Tsubura
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

10.  [Concentration of intravenously administered gammaglobulin preparations in dog skin (author's transl)].

Authors:  J Ring; K H Duswald; T Bachmann; W Stephan; W Brendel
Journal:  Arch Dermatol Res       Date:  1977-12-27       Impact factor: 3.017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.